Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
May 31, 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate
May 19, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration...
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
May 13, 2022 17:01 ET
|
Blue Water Vaccines Inc.
Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
April 21, 2022 08:45 ET
|
Blue Water Vaccines Inc.
CINCINNATI, April 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today...
Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 20, 2022 09:25 ET
|
Blue Water Vaccines Inc.
CINCINNATI, April 20, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 13, 2022 09:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, April 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
April 11, 2022 09:56 ET
|
Blue Water Vaccines Inc.
BWV-101 - Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research CINCINNATI, April 11, 2022 (GLOBE...
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
March 22, 2022 07:00 ET
|
Blue Water Vaccines Inc.
Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing...
Blue Water Vaccines Announces Closing of Initial Public Offering
February 23, 2022 16:51 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, today announced the closing...